Precision BioSciences, Inc. Common Stock (DTIL) is a publicly traded Healthcare sector company. As of May 21, 2026, DTIL trades at $7.18 with a market cap of $179.58M and a P/E ratio of -3.32. DTIL moved +3.77% today. Year to date, DTIL is +75.98%; over the trailing twelve months it is +47.13%. Its 52-week range spans $3.53 to $9.81. Analyst consensus is strong buy with an average price target of $36.33. Rallies surfaces DTIL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Precision BioSciences Expands ELIMINATE-B Trial with France and Romania Sites, Screening Q2 2026: Precision BioSciences received CTA approval to expand its global ELIMINATE-B trial into France and Romania, adding to existing sites in the UK, Moldova, New Zealand, Hong Kong and the US. Site initiation is underway with initial patient screening for PBGENE-HBV expected in Q2 2026.
| Metric | Value |
|---|---|
| Price | $7.18 |
| Market Cap | $179.58M |
| P/E Ratio | -3.32 |
| EPS | $-2.14 |
| Dividend Yield | 0.00% |
| 52-Week High | $9.81 |
| 52-Week Low | $3.53 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $45.07M |
| Net Income | $-43.60M |
| Gross Margin | 0.00% |
3 analysts cover DTIL: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $36.33.